{"id":"retapamulin-altabax","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1658","moleculeType":"Small molecule","molecularWeight":"517.78"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Retapamulin is a pleuromutilin antibiotic that selectively binds to the bacterial 50S ribosomal subunit and inhibits peptide bond formation, blocking protein synthesis. This mechanism is selective for bacteria and has minimal effect on human mitochondrial ribosomes. It is bacteriostatic, stopping bacterial growth rather than directly killing the organisms.","oneSentence":"Retapamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing bacterial growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:45.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Impetigo (skin infection caused by Staphylococcus aureus or Streptococcus pyogenes)"}]},"trialDetails":[{"nctId":"NCT01591785","phase":"NA","title":"Treatment of Staphylococcus Aureus Colonization in Hand Eczema","status":"COMPLETED","sponsor":"Gary Goldenberg","startDate":"2012-01","conditions":"Hand Eczema, Foot Eczema","enrollment":60},{"nctId":"NCT03304873","phase":"PHASE3","title":"Retapamulin as a Decolonizing Agent for MRSA","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-12-01","conditions":"MRSA","enrollment":47},{"nctId":"NCT00856089","phase":"PHASE4","title":"Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization","status":"WITHDRAWN","sponsor":"Ochsner Health System","startDate":"2009-05","conditions":"Methicillin-resistant Staphylococcus Aureus","enrollment":""},{"nctId":"NCT01461668","phase":"PHASE4","title":"Retapamulin for Reducing MRSA Nasal Carriage","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2012-07","conditions":"Methicillin-Resistant Staphylococcus Aureus","enrollment":53},{"nctId":"NCT01812382","phase":"PHASE1","title":"Retapamulin Microdialysis Feasibility Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-02","conditions":"Skin Infections, Bacterial","enrollment":3},{"nctId":"NCT00852540","phase":"PHASE3","title":"Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-04","conditions":"Skin Infections, Bacterial","enrollment":410},{"nctId":"NCT00903279","phase":"PHASE2","title":"Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery","status":"WITHDRAWN","sponsor":"Bay Pines VA Healthcare System","startDate":"2009-08","conditions":"Orthopedic Procedures, Methicillin-resistant Staphylococcus Aureus","enrollment":""},{"nctId":"NCT00133874","phase":"PHASE3","title":"Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Skin Infections, Bacterial","enrollment":520},{"nctId":"NCT00555061","phase":"PHASE4","title":"Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Skin Infections, Bacterial","enrollment":60},{"nctId":"NCT00539994","phase":"PHASE2","title":"Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Infections, Bacterial","enrollment":57},{"nctId":"NCT00684177","phase":"PHASE3","title":"Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-05","conditions":"Skin Infections, Bacterial","enrollment":508},{"nctId":"NCT00133848","phase":"PHASE3","title":"Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-04","conditions":"Impetigo","enrollment":210},{"nctId":"NCT01064947","phase":"PHASE4","title":"Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2010-02","conditions":"Atopic Dermatitis, Secondary Infection","enrollment":29},{"nctId":"NCT01397461","phase":"PHASE3","title":"Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo","status":"COMPLETED","sponsor":"Ferrer Internacional S.A.","startDate":"2012-03","conditions":"Impetigo","enrollment":465},{"nctId":"NCT01126268","phase":"PHASE4","title":"Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2010-04","conditions":"Impetigo, Folliculitis, Secondarily Infected Eczema","enrollment":38},{"nctId":"NCT01445600","phase":"","title":"ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11","conditions":"Skin Infections, Bacterial","enrollment":3612},{"nctId":"NCT00871208","phase":"PHASE4","title":"Trial of Treatment of Atopic Dermatitis With Concurrent Altabax® and Topical Low-Potency Corticosteroids Versus Low-Potency Corticosteroid Mono-therapy","status":"WITHDRAWN","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2009-05","conditions":"Atopic Dermatitis","enrollment":""},{"nctId":"NCT01153828","phase":"","title":"EU PV for Retapamulin-Prescribing","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11","conditions":"Impetigo","enrollment":1},{"nctId":"NCT01153880","phase":"","title":"United States Pharmacovigilence Retapamulin-Prescribing","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-12","conditions":"Skin Infections, Bacterial","enrollment":1}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"COMPLEX REGIONAL PAIN SYNDROME"},{"count":1,"reaction":"CONDITION AGGRAVATED"},{"count":1,"reaction":"DERMATITIS"},{"count":1,"reaction":"EXCORIATION"},{"count":1,"reaction":"IDIOSYNCRATIC DRUG REACTION"},{"count":1,"reaction":"NEUROPATHY PERIPHERAL"},{"count":1,"reaction":"PARAESTHESIA"},{"count":1,"reaction":"PARONYCHIA"},{"count":1,"reaction":"PRURITUS"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Altabax"],"phase":"marketed","status":"active","brandName":"Retapamulin (Altabax)","genericName":"Retapamulin (Altabax)","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Retapamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, thereby preventing bacterial growth. Used for Impetigo (skin infection caused by Staphylococcus aureus or Streptococcus pyogenes).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}